{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-191553","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.042076+00:00","generated_at":"2026-05-15T01:35:59.659139+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M","bullets":["Record net sales $150.6M (+41% YoY, +39% constant currency).","U.S. Glaucoma net sales $93.5M (+58% YoY); Glaucoma total $129.3M (+47% YoY).","GAAP net loss ($0.34)/share; non-GAAP net loss ($0.18)/share; operating loss narrowed YoY.","FY2026 net sales guidance raised to $620-635M from prior $600-620M.","Cash $280.5M, no debt; GAAP gross margin ~78%, non-GAAP ~84%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-191553","json":"https://secwatch.observer/filing/0001193125-26-191553.json","markdown":"https://secwatch.observer/filing/0001193125-26-191553.md","text":"https://secwatch.observer/filing/0001193125-26-191553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/0001193125-26-191553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/gkos-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:35:59.659139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6131ca75c4b27ea1cee0d9b01868d7d435c581fe","claim":"GLAUKOS Corp reported the first quarter ended March 31, 2026 results: revenue $150.6 million, net income $19.8 million, EPS ($0.34) per diluted share. Guidance raised.","evidence_excerpt":"of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: • Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. • Glaucoma record net sales of $129.3 million in Q1 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/0001193125-26-191553-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$150.6 million"},{"label":"Net income","value":"$19.8 million"},{"label":"EPS","value":"($0.34) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}